R-DXd clinical trials
R-DXd is named as an intervention in 10 current clinical trials in our USA, Spain, Israel, South Korea, Taiwan, Italy, Canada, China, Poland, UK, Switzerland, Australia, Germany, France, Turkey, Japan, Czechia, Portugal, Brazil, Austria, Belgium and Denmark registers. 5 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Merck Sharp & Dohme LLC (7). The most-studied condition is Ovarian Cancer.
Where R-DXd is approved
All regulators →- 1 EU orphan designation, most recently for treatment of ovarian cancer (19 Feb 2024, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Patient leaflets for R-DXd
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of R-DXd
10 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with R-DXd
14 conditionsAll 14 conditions
| Condition (as registered) | Trials |
|---|---|
| Ovarian Cancer | 2 |
| Peritoneal Cancer | 2 |
| Fallopian Tube Cancer | 2 |
| Ovarian Neoplasms | 1 |
| Ovarian Cancer Recurrent | 1 |
| Solid Cancer | 1 |
| Gastrointestinal Cancer | 1 |
| Lung Neoplasm | 1 |
| Small Cell Lung Carcinoma | 1 |
| Renal Cell Carcinoma | 1 |
| Ovarian Tumor | 1 |
| Advanced Solid Tumor | 1 |
| Metastatic Solid Tumors | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 7 |
| Daiichi Sankyo | 3 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about R-DXd trials
How many clinical trials are testing R-DXd?
10 current trials in our USA, Spain, Israel, South Korea, Taiwan, Italy, Canada, China, Poland, UK, Switzerland, Australia, Germany, France, Turkey, Japan, Czechia, Portugal, Brazil, Austria, Belgium and Denmark registers name R-DXd (also registered as MK-5909) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are R-DXd trials recruiting patients?
Yes. 5 of the 10 trials are recruiting: 5 with sites in USA, 3 with sites in Spain, 4 with sites in Israel, 3 with sites in South Korea, 4 with sites in Taiwan, 2 with sites in Italy, 2 with sites in Canada, 2 with sites in China, 2 with sites in Poland, 3 with sites in UK, 1 with sites in Switzerland, 2 with sites in Australia, 2 with sites in Germany, 1 with sites in France, 2 with sites in Turkey, 1 with sites in Japan, 1 with sites in Czechia, 1 with sites in Portugal and 1 with sites in Brazil. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors R-DXd clinical trials?
Merck Sharp & Dohme LLC (7) and Daiichi Sankyo (3). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how R-DXd works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how R-DXd works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists R-DXd (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.